Corbus Pharmaceuticals Holdings, Inc. (CRBP)
After hours:
| Previous close | 0.2823 |
| Open | 0.2957 |
| Bid | 0.2601 x 1000 |
| Ask | 0.2518 x 4000 |
| Day's range | 0.2503 - 0.3079 |
| 52-week range | 0.2080 - 1.9700 |
| Volume | |
| Avg. volume | 1,361,304 |
| Market cap | 31.539M |
| Beta (5Y monthly) | 2.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of complement (C5)NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today announced the appointment of Rachelle
- GlobeNewswire
uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
Biotech Executive Brings Extensive Experience Developing Advanced Therapies and Regenerative Medicines Rachelle Jacques Newly elected uniQure board member, Rachelle Jacques LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the Board’s Audi
- GlobeNewswire
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through business development continues to be a priorityCash and investments on hand of $114M provides projected runway into first quarter of 2024 Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today prov
